Bacterial prostatitis enhances 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced cancer at multiple sites

Cancer Prevention Research

Volumn 8, Issue 8, 2015, Pages 683-692

  Sfanos, Karen S ^a,b   Canene Adams, Kirstie ^a   Hempel, Heidi ^a   Yu, Shu Han ^a   Simons, Brian W ^a   Schaeffer, Anthony J ^c   Schaeffer, Edward M ^a   Nelson, William G ^a,b   De Marzo, Angelo M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; INTERLEUKIN 12; INTERLEUKIN 6; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO(4,5-B)PYRIDINE; CARCINOGEN; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; ESCHERICHIA COLI; HEALTH STATUS; MULTIPLE CANCER; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROSTATITIS; RAT; TIME OF DEATH; TUMOR INVASION; TUMOR VOLUME; ANIMAL; CELL TRANSFORMATION; COMPLICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; FISCHER 344 RAT; MALE; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROSTATIC NEOPLASMS;

ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; PROSTATITIS; RATS; RATS, INBRED F344;

EID: 84942039125     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0090     Document Type: Article

References (39)

1. Wild CP. Complementing the genome with an exposome: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:1847-50.
2. Sugimura T. Nutrition and dietary carcinogens. Carcinogenesis 2000; 21:387-95.
3. Nelson WG. Prostate cancer prevention. J Nutr 2004;134:3211S-2S.
4. Schut HAJ, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis 1999;20:353-68.
5. Sander A, Linseisen J, Rohrmann S. Intake of heterocyclic aromatic amines and the risk of prostate cancer in the EPIC-Heidelberg cohort. Cancer Causes Control 2011;22:109-14.
6. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Chao A, Patel AV, et al. Meat consumption among black and white men and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2006;15:211-6.
7. Sinha R, Park Y, Graubard BI, Leitzmann MF, Hollenbeck A, Schatzkin A, et al. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am J Epidemiol 2009;170:1165-77.
8. Koutros S, Cross AJ, Sandler DP, Hoppin JA, Ma X, Zheng T, et al. Meat and meat mutagens and risk of prostate cancer in the agricultural health study. Cancer Epidemiol Biomarkers Prev 2008;17:80-7.
9. John EM, Stern MC, Sinha R, Koo J. Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. Nutr Cancer 2011;63:525-37.
10. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 1997;57:195-8.
11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
12. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
13. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
14. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol 2013;1:3-11.
15. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215.
16. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 2008;68:306-20.
17. Bergh J, Marklund I, Thellenberg-Karls C, Gronberg H, Elgh F, Alexeyev OA. Detection of Escherichia coli 16S RNA and cytotoxic necrotizing factor 1 gene in benign prostate hyperplasia. Eur Urol 2007;51:457-62; discussion 62-3.
18. Yanamandra K, Alexeyev O, Zamotin V, Srivastava V, Shchukarev A, Brorsson A-C, et al. Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS ONE 2009;4:e5562.
19. Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc Natl Acad Sci U S A 2009;106:3443-8.
20. Boehm BJ, Colopy SA, Jerde TJ, Loftus CJ, Bushman W. Acute bacterial inflammation of the mouse prostate. Prostate 2012;72:307-17.
21. Elkahwaji JE, Hauke RJ, Brawner CM. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer 2009;101:1740-8.
22. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ. Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol 2010;176:2259-68.
23. Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, et al. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol 2015;235:478-89.
24. Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R. Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 2006;8:708-15.
25. Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res 2007;67:1378-84.
26. Canene-Adams K, Sfanos KS, Liang C-T, Yegnasubramanian S, Nelson WG, Brayton C, et al. Dietary chemoprevention of PhIP induced carcinogenesis in male Fischer 344 rats with tomato and broccoli. PLoS ONE 2013;8:e79842.
27. Rudick CN, Berry RE, Johnson JR, Johnston B, Klumpp DJ, Schaeffer AJ, et al. Uropathogenic Escherichia coli induces chronic pelvic pain. Infect Immun 2011;79:628-35.
28. Johnson JR, Delavari P, Kuskowski M, Stell AL. Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli. J Infect Dis 2001;183:78-88.
29. Johnson JR, Kuskowski MA, Gajewski A, Soto S, Horcajada JP, de Anta MTJ, et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis 2005;191:46-50.
30. Shirai T, Cui L, Takahashi S, Futakuchi M, Asamoto M, Kato K, et al. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett 1999;143:217-21.
31. Sharma OP, Adlercreutz H, Stranberg JD, Zirkin BR, Coffey DS, Ewing LL. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 1992;43:557-64.
32. Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JLA, Doernte AL, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010;59:88-97.
33. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006;66:7395-400.
34. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among us solid organ transplant recipients. JAMA 2011;306:1891-901.
35. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7.
36. Drachenberg DE, Elgamal A-AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33.
37. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-6.
38. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-9.
39. Yu S-H, Zheng Q, Esopi D, Macgregor-Das A, Luo J, Antonarakis ES, et al. A paracrine role for IL-6 in prostate cancer patients: Lack of production by primary or metastatic tumor cells. Cancer Immunol Res 2015;doi:10.1158/2326-6066.